Authors:
LO MW
TOH J
EMMERT SE
RITTER MA
FURTEK CI
LU H
COLUCCI WS
URETSKY BF
RUCINSKA E
Citation: Mw. Lo et al., PHARMACOKINETICS OF INTRAVENOUS AND ORAL LOSARTAN IN PATIENTS WITH HEART-FAILURE, Journal of clinical pharmacology, 38(6), 1998, pp. 525-532
Citation: Ma. Ritter et al., AN IMPROVED METHOD FOR THE SIMULTANEOUS DETERMINATION OF LOSARTAN ANDITS MAJOR METABOLITE, EXP3174, IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION, Journal of pharmaceutical and biomedical analysis, 15(7), 1997, pp. 1021-1029
Authors:
GOLDBERG MR
LO MW
CHRIST DD
CHIOU R
FURTEK CI
AMIT O
CARIDES A
BIOLLAZ J
PIGUET V
NUSSBERGER J
BRUNNER HR
Citation: Mr. Goldberg et al., DUP-532, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST - FIRST ADMINISTRATIONAND COMPARISON WITH LOSARTAN, Clinical pharmacology and therapeutics, 61(1), 1997, pp. 59-69
Authors:
MCCREA JB
LO MW
FURTEK CI
RITTER MA
CARIDES A
WALDMAN SA
BJORNSSON TD
GOLDBERG MR
Citation: Jb. Mccrea et al., KETOCONAZOLE DOES NOT EFFECT THE SYSTEMIC CONVERSION OF LOSARTAN TO E-3174, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 44-44
Authors:
LO MW
GOLDBERG MR
MCCREA JB
LU H
FURTEK CI
BJORNSSON TD
Citation: Mw. Lo et al., PHARMACOKINETICS OF LOSARTAN, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST, AND ITS ACTIVE METABOLITE EXP3174 IN HUMANS, Clinical pharmacology and therapeutics, 58(6), 1995, pp. 641-649